 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

PureTech Health notes Karuna Therapeutics submits KarXT NDA to FDA

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Karuna Therapeutics...

KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia

Karuna Therapeutics submits NDA to FDA for KarXT

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions...

Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia

Maryland State Retirement  Pension System bought a new position in Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report) in the 2nd quarter, according to its most recent Form 13F filing...

Maryland State Retirement & Pension System Takes $609,000 Position in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Maryland State Retirement  Pension System bought a new stake in shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report) in the 2nd quarter, according to its most recent filing with...

Maryland State Retirement & Pension System Buys Shares of 2,810 Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Karuna Therapeutics, Inc. (NASDAQ:KRTX  Get Free Report) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 1,350,000 shares, a...

Short Interest in Karuna Therapeutics, Inc. (NASDAQ:KRTX) Decreases By 6.9%

This is a signal that KRTX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Karuna Therapeutics (KRTX, $180.9) Stochastic Oscillator left the oversold zone on September 15, 2023

Chief Medical Officer Stephen Brannan Sells 5,000 Shares of Karuna Therapeutics Inc (KRTX)

Guggenheim Capital LLC cut its holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX  Free Report) by 37.7% during the 1st quarter, according to its most recent disclosure with the SEC. The...

Guggenheim Capital LLC Has $1.26 Million Holdings in Karuna Therapeutics, Inc. (NASDAQ:KRTX)

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Watchers	2,728
52-Wk Low	$159.73
52-Wk High	$245.00

Market Cap	$6.37B
Volume (M)	95,228.00
52-Wk High	$245.00
52-Wk Low	$159.73

Current Price	$162.87
Prev Close	$169.09
Open	$171.70
Dividend Yield	0.00%
50-Day Moving Average	$182.12
Beta	1.14
Avg. Volume	272,589.13
PE Ratio	-16.66

52-Week High	$245.00
52-Week Low	$159.73
Market Capitalization	$6.37B
EPS	-$10.15
Price to Book	4.48
Revenue Per Employee	$28,633.33
Enterprise Value/EBITDA	-17.06

KRTX Karuna Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals